



Press Release

Friday, September 25, 2009

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531, NSE: STAR

STRIDES ARCOLAB ANNOUNCES THE RETAIL LAUNCH OF STARFLU™ (OSELTAMIVIR) FOR THE TREATMENT OF 'INFLUENZA – A (H1N1)'

Strides Arcolab Limited (Strides) today said that it has launched its anti H1N1 drug – Starflu in retail. Starflu is the generic version of drug Oseltamivir and is available in 75 mg capsules in a strip of 10's, the MRP for which is Rs 460 per strip.

The Strides move is subsequent to the Indian Government's approval of restricted retail sale of Oseltamivir (Tamiflu) for H1N1 treatment. This will allow the purchase of Oseltamivir from designated chemists with Schedule X licenses, by those who have doctor prescriptions.

The retail effort for Starflu is being carried out by the Domestic Critical Care Division of Strides. Starflu is being made available in the 480 odd designated chemists/pharmacies with the required schedule X license.

Starflu is manufactured by Strides in its USFDA approved and WHO pre-qualified oral dosage forms manufacturing facility in Bangalore. Strides has also conducted necessary bioequivalence studies and established bioequivalence of its product with Tamiflu®.

Strides is amongst the few manufacturers who have been selected to supply the generic version of Oseltamivir to Government.

Nitin Ghadiyar, President – Strides Arcolab Limited stated "Strides has the requisite stocks of Starflu to adequately supply and service the retail demand for this drug".

Strides Overview

Strides, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a Bangalore, India head quartered global pharmaceutical company. Strides manufactures pharmaceutical formulations in various dosage forms including sterile injectables with dedicated facilities for Penicillin and Penams, Cephalosporins, Oncolytics and lyophilized injectable products. The company also manufactures pharmaceutical formulations in oral dosage

forms, including capsules & tablets and Softgel capsules. Strides operates in and has significant presence in Australasia, Africa and India and through a series of strategies is expanding its North American and European growth. The company has series of joint ventures and front-ended operations in major markets and is a majority stakeholder of Ascent Pharmahealth Limited (APH), an ASX listed Company. The company also collaborates closely with Global Drug Agencies and US PEPFAR and the UNICEF to supply a range of affordable generic pharmaceutical products used in the treatment of HIV, TB and Malaria.

Strides has manufacturing facilities in Bangalore, India and overseas facilities in Milan, Warsaw, Singapore and Lagos. The Indian manufacturing facilities are approved by all major regulatory bodies. Strides employs approximately 2,500 people across the globe. Strides also has a marketing presence in over 50 countries.

Additional information is available at the company's website at www.stridesarco.com

For further information, please contact

<p><i>For further details</i></p> <p>Mr. Nitin Ghadiyar, President Tel: +91-80-6658 0739 / 230</p> <p><i>For enquiries:</i></p> <p>Silwin.nr@stridesarco.com / Shamit.g@stridesarco.com</p> <p><i>For Company information:</i></p> <p>Mr. Kannan. N, Company Secretary Tel: +91 80 66580751</p>	<p>Mahesh Nair, Corporate Voice/ Weber Shandwick Mobile : +91 98803 76648 Email: maheshn@corvoshandwick.co.in</p> <p>Ms. Kasturi Wasmatar Corporate Voice/ Weber Shandwick Mobile : +91 99167 28393</p> <p>Email: kasturi@corvoshandwick.co.in</p>
---	--